ProKidney Set to Present Novel CKD Research at Kidney Week
Exciting News from ProKidney Corp.
ProKidney Corp. (NASDAQ: PROK), known for its innovative solutions in chronic kidney disease (CKD), is thrilled to announce that it will present two significant abstracts at the American Society of Nephrology's (ASN) Kidney Week 2025. This annual conference, bringing together experts and researchers in nephrology, offers a platform for the latest advancements in kidney health. ProKidney's participation underlines its commitment to addressing critical aspects of CKD through cellular therapeutics.
Highlights of the Presentation
Among the presentations will be a late-breaking poster detailing the Phase 2 REGEN-007 study results. This study investigates the potential of ProKidney's lead product, rilparencel, in treating diabetes-related kidney damage. The REGEN-007 study shows promise in energizing the conversation around effective treatments for CKD and diabetes, which often go hand-in-hand. ProKidney’s emphasis on cellular therapy is positioned to make a significant impact on patient outcomes.
About the Late-Breaking Presentation
Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results)
Session Title: Late-Breaking Science Posters [LB-PO]
Session Date, Time: November 6, 2025, from 10:00 AM to 12:00 PM CST
Poster Board #: TH-PO1203
Exploring Further Research Topics
In addition to the late-breaking poster, ProKidney will also present another impactful poster titled, Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel. This presentation will delve into how understanding inflammatory profiles can enhance the development of individualized therapies for CKD patients, further showcasing ProKidney's commitment to innovative research.
Other Poster Presentation Details
Session Title: Development, Stem Cells, and Regenerative Medicine [PO0600]
Session Date, Time: November 6, 2025, from 10:00 AM to 12:00 PM CST
Poster Board #: TH-PO0575
Company Commitment to Knowledge Sharing
Post-event, ProKidney aims to promote transparency and knowledge sharing by making the poster presentations available on its official website. This effort illustrates ProKidney’s dedication not only to innovation in product development but also to disseminating valuable research findings within the medical community.
Availability of Poster Presentations
After the conference, attendees and interested parties can find copies of the presentations on the company's website at https://prokidney.com/our-technology/publications/.
ProKidney's Mission in CKD
Founded in 2015, ProKidney is a frontrunner in CKD treatment through advanced cellular therapies. The company’s flagship product, rilparencel, is designed to provide innovative treatment options for patients facing advanced CKD and type 2 diabetes. ProKidney's research continues to set new standards in regenerative medicine, highlighting the potential for improved patient care.
Stay Updated with ProKidney
To keep pace with advancements in CKD therapies, stakeholders are encouraged to follow ProKidney's developments. The company is active in exploring new treatments aimed at preserving kidney function, which is of critical importance given the increasing prevalence of CKD worldwide.
Contact Information
ProKidney Contact
Ethan Holdaway
Email: Ethan.Holdaway@prokidney.com
Media Contact
Audra Friis
Email: audrafriis@sambrown.com
Investor Relations Contact
Daniel Ferry
Email: Daniel@lifesciadvisors.com
Frequently Asked Questions
What is the main focus of ProKidney Corp.?
ProKidney Corp. focuses on innovative cellular therapeutics for treating chronic kidney disease (CKD).
When will ProKidney present its research?
The presentations at the ASN Kidney Week are scheduled for November 6, 2025.
What are the key topics being presented?
Key topics include the Phase 2 REGEN-007 study results and the inflammatory profile of the therapy candidate rilparencel.
Where can I find more information about the presentations?
Copies of the presentations will be available on ProKidney's website after the event.
How can I contact ProKidney for inquiries?
Contact Ethan Holdaway at Ethan.Holdaway@prokidney.com for more information.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.